Tizos powder for injection
Dexa Medica
Ingredients in every vial
| Ceftizoxime | 1000 mg |
Each package contains
Other details
| Flavour | None |
W.H.O. classification
| ATC Level 1 | J - Antiinfectives for systemic use |
| ATC Level 2 | J01 - Antibacterials for Systemic Use |
| ATC Level 3 | J01D - Other Beta-Lactam Antibacterials in ATC |
Warnings
Pregnancy
Lactation
Alcohol
Machinery
Available in
 |
Indonesia |
Dosage information
18 YEARS OLD AND ABOVE
• Intravenous injection
Usually 0.5-2 g/day of ceftizoxime is administered intravenously in 2-4 equally divided doses, increased to 4 g/day for severe or intractable infections, according to the age and condition of the patient.
• Intramuscular injection
Usually 0.5-2 g/day of ceftizoxime is administered intramuscularly in 2-4 equally divided doses, according to the age and condition of the patient
6 MONTHS TO 18 YEARS OLD
• Intravenous injection
For children 6 months or older usually 40-80 mg/kg/day of ceftizoxime in 2-4 equally divided doses, increased to 120 mg/kg/day for severe or intractable infections, according to the age and condition of the patient.
Indication
The following infections caused by ceftizoxime susceptible Streptococcus sp. (excluding Enterococci), Streptococcus pneumoniae, Haemophilus influenzae, Escherichia coli, Klebsiella sp., Proteus sp., Serratia sp., Enterobacter sp., Citrobacter sp., Peptococcus sp., Peptostreptococcus sp., and Bacteroides sp.
– Septicemia, bacterial endocarditis.
– Secondary infections of wounds or burns.
– Bronchitis, infected bronchiectasis, secondary infections of chronic respiratory tract diseases, pneumonia, pulmonary suppuration, pyothorax.
– Cholangitis, cholecystitis.
– Peritonitis.
– Pyelonephritis, cystitis, prostatitis.
– Meningitis caused by H. influenzae.